Avatrombopag in the Treatment of Adult Immune Thrombocytopenia (ITP) with Autoantibodies

This phase 4 study by the Institute of Hematology & Blood Diseases Hospital is a prospective, open-label, single center clinical trial to evaluate the efficacy and safety of avatrombopag in Chinese adult patients (over 18 years) with ITP (Primary or Secondary). Participants must have autoantibody failure due to intolerance or resistance to eltrombopag or hetrombopag therapy. Participants must have platelet counts below 30,000 µL and must not have used Rituximab in the last three months or have active thyroid disease.




back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo